Resource center

Every winter, millions reach for cold and flu products, yet few appreciate the clinical rigor behind those claims of “faster relief” or “reduced cough duration.” Running studies to substantiate these types of claims can be challenging.Unlike chronic or preventive conditions, cold and flu symptoms appear suddenly, usually resolve quickly and vary widely across individuals and seasons.

The digital transformation of the fertility space has brought us everything from period tracking apps to FDA-cleared digital contraceptives. Yet these tools are often grouped together under broad categories that obscure critical differences in their purpose and effectiveness.

Consumer health is a $6.3 trillion mainstream market with consumers prioritizing solutions that help them feel and look better and live longer. Yet in this crowded, fast-moving space, one principle stands above all others: trust is the foundation of strong consumer health brands.

We're excited to launch Off Protocol, a podcast that challenges the status quo of clinical trials and explores the realities of clinical research.

For decades, women have been underrepresented in clinical trials — a gap that’s not just unfortunate but dangerous. When research isn’t representative of half the global population, we can’t truly develop treatments that are safe and effective for all.

Finding patients for clinical trials is only half the battle. True clinical trial success comes from clear communication, personalisation, and keeping participants engaged.

Ovarian cancer remains one of the most lethal gynecological cancers, largely because diagnosis often comes too late. Around 70% of cases are detected at an advanced stage, with approximately 300,000 new cases each year.

Deciding which trial activities to manage internally and when to engage a diagnostics-focused CRO can significantly impact timelines, data quality, and ultimately, market success.

In oncology diagnostics, selecting between biobank specimens and prospective clinical trials for assay validation is not merely a methodological choice—it’s a strategic imperative.

For sponsors developing rapid infectious disease diagnostics, the landscape is shifting fast. Traditional lab tests take hours or days, but rapid diagnostics deliver results in minutes. This shift creates a significant challenge: clinical trial strategies designed for slow, centralized tests won’t work for fast, decentralized ones.